E
Emma Duffield
Researcher at AstraZeneca
Publications - 20
Citations - 9873
Emma Duffield is an academic researcher from AstraZeneca. The author has contributed to research in topics: Gefitinib & Population. The author has an hindex of 13, co-authored 18 publications receiving 9065 citations.
Papers
More filters
Journal ArticleDOI
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok,Yi-Long Wu,Sumitra Thongprasert,Chih-Hsin Yang,Da Tong Chu,Nagahiro Saijo,Patrapim Sunpaweravong,Baohui Han,Benjamin Margono,Benjamin Margono,Yukito Ichinose,Yutaka Nishiwaki,Yuichiro Ohe,Jin Ji Yang,Busyamas Chewaskulyong,Haiyi Jiang,Emma Duffield,Claire Watkins,Alison Armour,Masahiro Fukuoka +19 more
TL;DR: Gefit inib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia and the presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.
Journal ArticleDOI
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka,Yi-Long Wu,Sumitra Thongprasert,Patrapim Sunpaweravong,Swan Swan Leong,Virote Sriuranpong,Tsu Yi Chao,Tsu Yi Chao,Kazuhiko Nakagawa,Da Tong Chu,Nagahiro Saijo,Emma Duffield,Yuri Rukazenkov,Georgina Speake,Haiyi Jiang,Alison Armour,Ka Fai To,James Chih-Hsin Yang,Tony Mok +18 more
TL;DR: EGFR mutations are the strongest predictive biomarker for PFS and tumor response to first-line gefitinib versus carboplatin/paclitaxel and the predictive value of EGFR gene copy number was driven by coexisting EGFR mutation (post hoc analysis).
Journal ArticleDOI
Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study
Lucio Crinò,Federico Cappuzzo,Petr Zatloukal,Martin Reck,Miloš Pešek,Joyce Thompson,Hugo Ford,Fred R. Hirsch,Marileila Varella-Garcia,Serban Ghiorghiu,Emma Duffield,Alison Armour,Georgina Speake,Michael Cullen +13 more
TL;DR: There was no statistical difference between gefitinib and vinorelbine in efficacy in chemotherapy-naïve, unselected elderly patients with advanced NSCLC, but there was better tolerability with gefithinib.
Journal ArticleDOI
Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer
Koichi Goto,Yukito Ichinose,Yuichiro Ohe,Nobuyuki Yamamoto,Shunichi Negoro,Kazuto Nishio,Yohji Itoh,Haiyi Jiang,Emma Duffield,Rose McCormack,Nagahiro Saijo,Tony Mok,Masahiro Fukuoka +12 more
TL;DR: These results merit further investigation to determine whether alternative sources of tumor DNA, such as cfDNA in serum, could be used for determining EGFR mutation status in future; currently, where a sample is available, analysis of tumor material is recommended.
Journal ArticleDOI
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).
Christie M. Ballantyne,Robert E. Weiss,Tiziano Moccetti,Anja Vogt,Bernd Eber,Froukje Sosef,Emma Duffield,Explorer Study Investigators +7 more
TL;DR: In this paper, the efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe 10 mg in patients at high risk of coronary heart disease were investigated.